Lawton v. Takeda Pharm. Co.

E-Law Admin/ November 22, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

Lawton v. Takeda Pharm. Co., 16-1382

In a qui tam action under the False Claims Act (FCA), 31 U.S.C. section 3729 et seq., and the False Claims Acts of 28 different states and the District of Columbia, alleges that defendants conspired in a fraudulent marketing campaign that caused third-parties to submit false reimbursement claims to government entities for off-label uses of Actos, a treatment for Type 2 diabetes, the district court’s dismissal of all claims is affirmed where plaintiff had not pled his claims with the particularity required by Federal Rule of Civil Procedure 9(b).

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/11/22



  • United States First Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar